XML 34 R23.htm IDEA: XBRL DOCUMENT v3.22.0.1
Interim Financial Statements and Basis of Presentation (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Mar. 31, 2021
Research and development expense $ 288,631 $ 18,864 $ 923,996 $ 32,773  
Common stock, shares authorized 250,000,000   250,000,000   250,000,000
Common stock, par or stated value per share $ 0.001   $ 0.001   $ 0.001
Common stock, shares issued 31,975,083   31,975,083   24,438,416
Common stock, shares outstanding 31,975,083   31,975,083   24,438,416
General and Administrative Expense [Member]          
Research and development expense     $ 15,397